APA (7th ed.) Citation

Mehrens, D., Kramer, K. K. M., Unterrainer, L. M., Beyer, L., Bartenstein, P., Froelich, M. F., . . . Kunz, W. G. (2023). Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer. Journal of the National Comprehensive Cancer Network, 21(1), . https://doi.org/10.6004/jnccn.2022.7070

Chicago Style (17th ed.) Citation

Mehrens, Dirk, et al. "Cost-effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer." Journal of the National Comprehensive Cancer Network 21, no. 1 (2023). https://doi.org/10.6004/jnccn.2022.7070.

MLA (9th ed.) Citation

Mehrens, Dirk, et al. "Cost-effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer." Journal of the National Comprehensive Cancer Network, vol. 21, no. 1, 2023, https://doi.org/10.6004/jnccn.2022.7070.